Ligand Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ligand Pharmaceuticals, Inc.
Becton Dickinson Receives FDA Clearance For Vaginal Panel To Detect Vaginitis
BD said its newly FDA-cleared Vaginal Panel can detect three most common infectious causes of vaginitis with a single swab, reducing the need for repeat testing.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends
From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
- Site Specific
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Ab Initio Biotherapeutics
- Crystal Bioscience, Inc.
- CyDex Pharmaceuticals, Inc.
- Icagen Pharmaceuticals, Inc.
- Metabasis Therapeutics, Inc.
- Neurogen Corporation
- Pharmacopeia, Inc.
- Pfenex Inc.
- Verrow Pharmaceuticals, Inc.
- Vernalis Group plc
- Cita NeuroPharmaceuticals
- Taurus Biosciences LLC
- xCella Biosciences, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.